Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
October 2, 2025Open Access

Supplementary Figure S7 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZiyi WangYZYu ZhangXLXiangdong Li

Discussion

Loading...

Member takes

Overview

Deletion of myeloid Trem2 reduces TGFβ in NASH, suggesting enhanced efficacy of checkpoint immunotherapy.

Key Points

  • Deletion of myeloid Trem2 notably reduces levels of TGFβ, enhancing immune response.
  • Key evidence shows significant decrease in TGFβ levels linked to myeloid Trem2 deletion.
  • This assessment utilizes targeted genetic deletion within the context of NASH-driven hepatocarcinogenesis.
  • These findings highlight possible therapeutic strategies to improve immunotherapy outcomes.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a219e9https://doi.org/10.1158/2326-6066.30255475
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure S1 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  2. 2Supplementary Figure S2 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  3. 3Supplementary Figure S6 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  4. 4Supplementary Figure S3 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  5. 5Supplementary Figure S4 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025